Immix Biopharma, Inc. 8-K

What Happened

• Immix Biopharma, Inc. (IMMX) announced on March 30, 2026 (via an 8-K and press release) that enrollment in its NEXICART-2 clinical trial of NXC-201 is complete.
• The company said topline results from the trial are expected in Q3 2026. The disclosure was made under Items 7.01 (Regulation FD disclosure) and 8.01 (Other events).

Key Details

• Date of disclosure: March 30, 2026.
• Trial: NEXICART-2 evaluating NXC-201; enrollment is complete.
• Timing: Topline results expected in Q3 2026.
• Document filed: Press release furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters

• Completion of enrollment is a major operational milestone—it removes patient recruitment as a near-term risk and signals the trial is moving into data collection/analysis.
• The Q3 2026 topline timing gives investors a clear upcoming catalyst for potential clinical and valuation impact.
• The 8-K provides no efficacy or safety results; investors should await the topline data for substantive information on trial outcomes.